



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
 CIN: L24230GJ2010PLC061123
 Ph #: 0265 2280550 Fax #: 2280880
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**UNAUDITED FINANCIAL RESULTS
 FOR THE PERIOD ENDED 31ST DECEMBER, 2014**

Rs. in lacs

	Particulars	STANDALONE					
		Quarter Ended			Period Ended		Year Ended
		December-14	September-14	December-13	December-14	December-13	March-14
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
PART- I							
1	(a) Net Sales / Income from Operations						
	Domestic	29,281	32,743	27,190	89,864	79,570	104,106
	Exports	21,233	21,562	20,579	63,320	59,701	80,793
	Total	50,514	54,305	47,769	153,184	139,271	184,899
	Less : Excise Duty	395	250	187	893	582	771
	Net Sales / Income from Operations	50,119	54,055	47,582	152,291	138,689	184,128
	(b) Other Operating Income	83	83	78	229	181	251
	Total Income from Operations	50,202	54,138	47,660	152,520	138,870	184,379
2	Expenses						
	(a) Decrease/(increase) in stock in trade and work in progress	(1,399)	(3,660)	(2,424)	(7,736)	(4,472)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	12,361	15,501	15,144	42,590	42,505	55,593
	(c) Purchase of traded goods	6,395	7,127	4,799	19,168	15,679	19,807
	(d) Employees' Cost	7,658	7,432	6,202	22,412	17,769	24,446
	(e) Marketing Expense	5,272	6,459	3,958	16,685	13,141	16,075
	(f) Research and Development Expense	2,559	2,770	2,727	8,083	7,917	10,510
	(g) Excise Duty	427	122	76	701	363	425
	(h) Other Expenditure	6,371	6,895	6,860	19,238	18,731	25,686
	Total Expenses	39,644	42,646	37,342	121,141	111,633	148,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10,558	11,492	10,318	31,379	27,237	35,902
4	Other Income	13	14	20	45	42	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,571	11,506	10,338	31,424	27,279	36,221
6	Depreciation	1,190	1,084	1,012	3,345	2,950	4,049
7	Interest (Net)	(42)	92	348	106	752	981
8	CSR Expense	91	83	-	239	-	-
9	Net Profit from Ordinary Activities before Tax	9,332	10,247	8,978	27,734	23,577	31,191
10	Tax Expense						
	Less : Provision for Current Tax	1,933	2,135	1,882	5,782	4,948	6,700
	Less /Add : Provision for Deferred Tax Liability/(Assets)	-	(293)	312	-	515	663
11	Net Profit from Ordinary Activities after Tax	7,399	8,405	6,784	21,952	18,114	23,828
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	-	-	59,199
14	Basic & Diluted EPS (Not Annualised)	3.92	4.46	3.60	11.64	9.61	12.64
A	PART- II						
1	Particulars of Shareholding						
	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS						
		Quarter Ended on 31st December, 2014					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	7					
	Disposed of during the quarter	7					
	Remaining unresolved at the end of the quarter	NIL					



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
 CIN: L24230GJ2010PLC061123
 Ph #: 0265 2280550 Fax #: 2280880
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**UNAUDITED FINANCIAL RESULTS
 FOR THE PERIOD ENDED 31ST DECEMBER, 2014**

Rs. In Lacs

Particulars		CONSOLIDATED					
		Quarter Ended			Period Ended		Year Ended
		December-14	September-14	December-13	December-14	December-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	PART- I						
	(a) Net Sales / Income from Operations						
	Domestic	29,281	32,743	27,190	89,864	79,570	104,106
	Exports	22,209	22,132	21,484	66,114	60,749	82,735
	Total	51,490	54,875	48,674	155,978	140,319	186,841
	Less : Excise Duty	395	250	187	893	582	771
	Net Sales / Income from Operations	51,095	54,625	48,487	155,085	139,737	186,070
	(b) Other Operating Income	83	83	78	229	181	251
	Total Income from Operations	51,178	54,708	48,565	155,314	139,918	186,321
2	Expenses						
	(a) Decrease/(increase) in stock in trade and work in progress	(1,399)	(3,660)	(2,424)	(7,736)	(4,472)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	12,361	15,501	15,144	42,590	42,505	55,593
	(c) Purchase of traded goods	6,471	7,126	4,799	19,243	15,679	19,807
	(d) Employees' Cost	7,916	7,677	6,418	23,154	17,985	24,700
	(e) Marketing Expense	5,615	7,010	4,346	17,821	13,529	16,618
	(f) Research and Development Expense	3,051	3,109	2,901	9,113	8,523	11,643
	(g) Excise Duty	427	122	76	701	363	425
	(h) Other Expenditure	6,488	6,997	7,082	19,687	19,164	25,829
	Total Expenses	40,930	43,882	38,342	124,573	113,276	150,550
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10,248	10,826	10,223	30,741	26,642	35,771
4	Other Income	13	14	20	45	42	319
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,261	10,840	10,243	30,786	26,684	36,090
6	Depreciation	1,190	1,084	1,012	3,345	2,950	4,049
7	Interest (Net)	(18)	104	348	142	752	981
8	CSR Expense	91	83	-	239	-	-
9	Net Profit from Ordinary Activities before Tax	8,998	9,569	8,883	27,060	22,982	31,060
10	Tax Expense						
	Less : Provision for Current Tax	1,933	2,136	1,978	5,804	5,046	6,847
	Less/(Add) : Provision for Deferred Tax Liability /(Assets)	-	(293)	312	-	515	663
11	Net Profit from Ordinary Activities after Tax	7,065	7,226	6,593	21,256	17,421	23,550
12	Share of Profit of Associates	1	1	-	4	-	-
13	Net Profit after Tax and share of profit of associates	7,066	7,227	6,593	21,260	17,421	23,550
14	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
15	Reserves excluding Revaluation Reserve	-	-	-	-	-	63,787
16	Basic & Diluted EPS (Not Annualised)	3.75	4.10	3.50	11.28	9.24	12.49
A	PART- II						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 31st December, 2014					
	Pending at the beginning of the quarter						NIL
	Received during the quarter						7
	Disposed of during the quarter						7
	Remaining unresolved at the end of the quarter						NIL

Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.

The key information on the standalone financial results are as under:

Particulars	Quarter Ended			Period Ended		Year Ended
	Dec-14	Sep-14	Dec-13	Dec-14	Dec-13	Mar-14
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net Sales / Income from Operations	50,202	54,138	47,660	152,520	138,870	184,379
Profit Before Tax	9,332	10,247	8,978	27,734	23,577	31,191
Profit After Tax	7,399	8,405	6,784	21,952	18,114	23,828

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17)
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 4th February, 2015

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com